Gilead Seeks to Tame Merck Case -- WSJ
03 May 2016 - 5:05PM
Dow Jones News
By Peter Loftus
A federal judge has allowed Gilead Sciences Inc. to submit
additional evidence in a drug-patent dispute with Merck & Co.,
after Gilead claimed a former Merck patent attorney lied under oath
in the case.
In March, a federal jury in San Jose, Calif., ordered Gilead to
pay Merck $200 million after finding that two U.S. patents held by
Merck and its partner, Ionis Pharmaceuticals Inc., were valid and
infringed by Gilead's multibillion-dollar hepatitis C drugs,
Sovaldi and Harvoni. The trial arose from Gilead's 2013 lawsuit
seeking a judgment that the Merck patents were invalid.
The patents cover a range of compounds treating hepatitis C.
Merck recently began selling its own hepatitis C drug,
Zepatier.
After the jury verdict and award in March, U.S. District Judge
Beth Labson Freeman presided over a bench trial in which Gilead
argued it shouldn't have to pay Merck because Merck was dishonest
in obtaining its patents. Gilead said that in 2004, Merck patent
attorney Philippe Durette had a conference call with employees of
Pharmasset Inc., in which he learned the chemical structure of an
experimental hepatitis C drug that Pharmasset was developing,
code-named PSI-6130. Gilead later spent more than $11 billion to
acquire Pharmasset and its hepatitis C drugs.
Gilead said Mr. Durette misused what he learned on the call to
subsequently change claims in pending Merck patent applications in
a way that would cover Pharmasset's technology.
A Merck spokeswoman said the jury reached the correct verdict,
and Merck believes the court will uphold it. Merck said Gilead's
arguments about Merck's conduct in obtaining its patents are
without merit.
Judge Freeman's final decision in the bench trial is pending. On
April 22, Gilead asked the judge to reopen the record for the bench
trial to allow it to submit additional information, claiming Mr.
Durette "lied on a critical issue in this case." At a hearing
Friday, the judge granted Gilead's request.
The 2004 call was part of confidential negotiations over a
potential deal for Merck to license PSI-6130 from Pharmasset, a
deal that never materialized, Gilead said.
In a deposition last year, Mr. Durette said he wasn't involved
in any such call, according to a Gilead court document.
But at the March trial, he changed his story and testified he
now remembered he was present for the call and learned the
structure of the compound, according to Gilead. He said he had
earlier forgotten about the call, according to Gilead.
Gilead wants to submit to the court additional excerpts of Mr.
Durette's deposition to give the judge a more complete record on
which to assess his conduct and candor.
Merck said in a court document that Mr. Durette initially didn't
remember being on the 2004 conference call, and that he acted
properly because he waited to change Merck's patent applications
until after Pharmasset published the structure of PSI-6130.
Mr. Durette couldn't immediately be reached to comment
Monday.
Write to Peter Loftus at peter.loftus@wsj.com
(END) Dow Jones Newswires
May 03, 2016 02:50 ET (06:50 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2024 to May 2024
Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024